New intravenous combination antibiotic for intra-abdominal and urinary tract infection

Zerbaxa contains the cephalosporin ceftolozane and the beta-lactamase inhibitor tazobactam.

Ceftolozane/tazobactam is effective against bacteria including Enterobacter cloacae, Escherichia coli and Klebsiella pneumoniae. | iStock
Ceftolozane/tazobactam is effective against bacteria including Enterobacter cloacae, Escherichia coli and Klebsiella pneumoniae. | iStock

Further information
View Zerbaxa drug record 
Summary of Product Characteristics
Manufacturer: Merck Sharp & Dohme

The combination is administered by intravenous infusion and is indicated for the treatment of complicated intra-abdominal infection, complicated urinary tract infection and acute pyelonephritis. Susceptible organisms include Enterobacter cloacae, Escherichia coli and Klebsiella pneumoniae.

In a trial in patients with complicated intra-abdominal infection, clinical cure rates for the ceftolozane/tazobactam combination were 95.9% in patients younger than 65 years (n=293) and 87.8% in those 65 years or older (n=82).

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Check on the latest drug supply issues with MIMS' shortages...

Novel MS drug gains NICE approval

Novel MS drug gains NICE approval

New NICE guidance recommends ocrelizumab (Ocrevus)...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

NICE recommends new triple therapy option for diabetes

NICE recommends new triple therapy option for diabetes

Ertugliflozin (Steglatro) can now be prescribed routinely...